Crypto rulebook, Genglycos, and FTC pricing scrutiny — August 17–23, 2026
A sourced weekly digest of SEC crypto rulemaking and enforcement, FDA approvals and AI-device policy, and FTC settlements, injunctions, and personalized-pricing scrutiny from August 17–23, 2026.
The week of August 17–23, 2026 produced 14 developments across the SEC, FDA, and FTC. The SEC proposed a crypto-asset offering framework and filed four new enforcement or investigative actions. The FDA approved a gene therapy, authorized a robotic blood-draw device, and opened a discussion on generative-AI medical devices. The FTC announced two monetary settlements, won a permanent merger injunction, opened a personalized-pricing policy process, and filed an amicus brief in biologic-drug litigation.
The immediate calendar items are the FDA's October 19 deadline for comments on docket FDA-2026-N-7874 and the SEC's October 20 deadline for comments on File No. S7-2026-27. The FTC's personalized-pricing release sets a 30-day period after Federal Register publication; the exact date was not announced in the material available for this issue.
At a glance
| Agency | Matter | Status and amount | Next action |
|---|---|---|---|
| SEC | Regulation Crypto Assets, File No. S7-2026-27 | Proposed rule; exemptions up to $5 million over four years and $75 million per 12 months; comments close October 20 | Crypto issuers, intermediaries, investors, and counsel should assess the proposed disclosure, reporting, safe-harbor, and state-law provisions. 1 |
| SEC | Tricolor Holdings; Daniel Chu, Jerome Kollar, Ameryn Seibold | Complaint over alleged double-pledging and misleading ABS disclosures; more than $1.9 billion raised and more than $945 million outstanding at bankruptcy | Track the SDNY case and preserve records tied to collateral, loan metrics, and investor disclosures. 2 |
| SEC | Jesse R. Mitchell and The Trade Desk | Insider-trading complaint; alleged profits of nearly $20,000 and more than $318,000; relief sought includes disgorgement, penalties, and a bar | Review earnings-access controls, blackout procedures, and options-trading restrictions. 3 |
| SEC | Gavin Wolfe, Jason Satsky, and South Jersey Industries | Insider-trading complaint; alleged profits of approximately $18.5 million and $515,000 for other traders; injunctions, disgorgement, penalties, and bars sought | Review banker access, deal-team information barriers, and personal-account surveillance. 4 |
| SEC | 1859 Operating and related respondents | Subpoena-enforcement action concerning a possible $42.7 million oil-lease offering; the SEC seeks an order compelling compliance | Preserve subpoena-response records and monitor the Northern District of Texas proceeding. 5 |
| FDA | Genglycos, Ultragenyx | Accelerated approval for GSDIa patients aged 8 and older; confirmatory trials required | Track post-approval commitments and labeling obligations. 6 |
| FDA | Aletta, Vitestro | De Novo authorization for an adult outpatient robotic blood-draw device; special controls apply | Build operating procedures around trained-phlebotomist oversight, labeling, performance testing, and clinical testing. 7 |
| FDA | GenAI-enabled medical devices, docket FDA-2026-N-7874 | Discussion paper; comments close October 19 | Manufacturers, clinicians, researchers, and patient groups should submit responses on risk, premarket, and postmarket questions. 8 |
| FTC | Doxo | $2.1 million settlement of allegations involving misleading search ads, biller impersonation, and add-on fees | Review bill-payment advertising, fee presentation, and consumer-routing controls. 9 |
| FTC | Henkel and Liquid Nails | Permanent injunction blocking the proposed $725 million acquisition after a seven-day trial | Treat the transaction as blocked and reassess merger, integration, and remedy plans. 10 |
| FTC | Personalized pricing, docket FTC-2026-1057 | Proposed enforcement policy statement; comments due 30 days after Federal Register publication | Monitor Federal Register publication and prepare a comment timetable. 11 |
| FTC | Manchester City Nissan | $4 million settlement resolving allegations involving deceptive fees | Review dealer fee disclosures and consent controls. 12 |
| FTC | CareFirst of Maryland v. Amgen | Amicus brief alleging Amgen acquired exclusive rights to patent applications shaped to cover Enbrel; monetary relief not stated | Monitor the court proceeding and assess implications for biologic competition and patent strategy. 13 |
SEC
Regulation Crypto Assets: two exemptions and a safe harbor
On August 18, the SEC proposed Regulation Crypto Assets, a new framework for certain investment contracts involving crypto assets. The proposal creates a startup exemption for offerings of up to $5 million during a four-year period and a fundraising exemption for offerings of up to $75 million during each 12-month period. Both paths require principles-based narrative disclosures; issuers using the larger exemption would also provide financial statements and ongoing reports. 14
The proposal also includes a conditional safe harbor from the term "investment contract" in the Securities Act and Exchange Act definitions of "security." A qualifying crypto asset would be treated outside an investment contract under the proposed conditions. The SEC would also preempt state registration and qualification requirements for covered offerings and certain secondary-market transactions. The Federal Register document identifies the affected framework as File No. S7-2026-27 and sets the comment deadline at October 20, 2026. 1
Legal teams should map current and planned token offerings against both exemptions, the proposed disclosure forms, the safe-harbor conditions, and the state-law provision. The SEC says issuers relying on the exemptions would remain subject to federal antifraud and antimanipulation rules. The proposal is a rulemaking, so its current status is proposed rather than operative law.
Tricolor Holdings: alleged double-pledging in ABS offerings
On August 18, the SEC charged former Tricolor Holdings CEO Daniel Chu, CFO Jerome Kollar, and Senior Director of Finance Ameryn Seibold. The complaint alleges that the executives helped double-pledge hundreds of millions of dollars of subprime auto loans across multiple asset-backed-securities offerings and lenders. The SEC says Tricolor raised more than $1.9 billion through ABS offerings and that more than $945 million of principal remained outstanding when the company entered bankruptcy in September 2025. 2
The SEC also alleges that offering materials and investor meetings portrayed Tricolor as financially sound, described collateral as free of other liens, and used loan metrics that made non-paying or defaulted loans appear current. The complaint seeks injunctions, disgorgement with prejudgment interest, civil penalties, and officer-and-director bars against Chu and Kollar. The case is a filed complaint in the U.S. District Court for the Southern District of New York; the requested relief remains pending. 15
Lenders, ABS sponsors, trustees, underwriters, and auditors should review collateral eligibility controls, lien representations, exception reporting, and the chain of approvals behind loan-pool metrics. The parallel criminal case announced by the U.S. Attorney's Office for the Southern District of New York adds a separate criminal-proceeding track to the SEC civil case.
Jesse R. Mitchell and The Trade Desk: earnings access and options
On August 21, the SEC announced charges against Jesse R. Mitchell, formerly The Trade Desk's Senior Director of Financial Planning and Analysis. The complaint alleges that Mitchell traded ahead of earnings releases. In one instance, he bought 3,850 shares before a positive second-quarter 2024 release and made nearly $20,000. In another, the SEC alleges that he bought out-of-the-money put options before a fourth-quarter 2024 release that contained the company's first revenue-guidance miss, then made more than $318,000 after the share price fell by over 30% the following day. 3
The SEC complaint alleges violations of Section 10(b) and Rule 10b-5, including trades during company blackout periods and a permanent employee ban on trading The Trade Desk options. The SEC seeks permanent injunctions, disgorgement with prejudgment interest, civil penalties, and an officer-and-director bar. The civil complaint is pending in the Southern District of New York, alongside a parallel criminal indictment announced on August 20. The SEC's 30% price figure describes the earlier earnings event, rather than a market reaction to this week's filing.
Companies should test whether earnings-access lists cover finance, forecasting, investor-relations, and support personnel; whether blackout controls reach derivatives; and whether surveillance can identify trades through connected accounts.
Gavin Wolfe and Jason Satsky: South Jersey Industries trading
On August 21, the SEC filed fraud charges against former investment bankers Gavin Wolfe and Jason Satsky over trading ahead of South Jersey Industries' February 24, 2022 acquisition announcement. The complaint alleges that Satsky, the lead banker advising South Jersey on the potential acquisition, tipped Wolfe with material nonpublic information. Wolfe allegedly bought more than 2.2 million shares and made approximately $18.5 million when the stock rose about 40% after the acquisition announcement. The SEC also alleges that Wolfe tipped other traders who generated approximately $515,000. 4
The SEC seeks permanent injunctions, civil penalties, officer-and-director bars, disgorgement and prejudgment interest against Wolfe, and conduct-based relief against Satsky. The entities through which Wolfe allegedly traded are named as relief defendants, with disgorgement and interest sought against them. The complaint is pending in the Southern District of New York.
Investment banks should check deal-team rosters, wall-crossing records, personal-account monitoring, and controls for former employees who retain access to transaction information. The price movement in the SEC's account belongs to the 2022 acquisition announcement.
1859 Operating: subpoena enforcement in an oil-lease investigation
On August 21, the SEC announced a subpoena-enforcement action filed against 1859 Operating, five affiliated entities, and six related individuals. The investigation concerns possible offering fraud involving fractional undivided working interests in oil leases. The SEC says the respondents raised approximately $42.7 million and produced about 8,344 documents from a potentially much larger responsive universe. The application also describes missed or canceled testimony dates. 5
The SEC seeks a court order compelling compliance with its investigative subpoenas. The matter remains a fact-finding investigation, and the SEC says it has not concluded that any individual or entity violated the federal securities laws. The next procedural step is the Northern District of Texas's consideration of the motion to compel.
Respondents and their counsel should preserve collection logs, production histories, custodian communications, and testimony scheduling records. Other companies facing SEC subpoenas should treat the filing as a reminder that extended production discussions do not replace compliance with an enforceable subpoena.
FDA
Genglycos: accelerated approval with confirmatory work ahead
On August 19, the FDA granted Genglycos (pariglasgene brecaparvovec-opnr) accelerated approval to Ultragenyx Pharmaceutical for adults and children aged 8 and older with glycogen storage disease type Ia. The therapy is approved to reduce daily cornstarch intake as an adjunct to nutritional management and is the first approved treatment for the condition. 6
The approval rests on reduction in daily cornstarch intake as a surrogate endpoint. Ultragenyx must complete additional clinical trials to confirm effectiveness. The immediate compliance task is to track those post-approval commitments alongside the label's warnings and the conditions attached to an accelerated approval. The approval changes patient access now, while the confirmatory evidence remains part of the product's regulatory path.
Aletta: De Novo authorization for robotic blood draws
On August 19, the FDA granted Vitestro De Novo marketing authorization for Aletta, the first standalone robotic device authorized to draw blood from an adult patient's arm without hands-on operator intervention. The device is limited to adult outpatient use and requires oversight by a supervisor trained in phlebotomy; one phlebotomist may oversee up to three devices. 7
The authorization establishes special controls covering labeling, performance testing, and clinical testing. The device initiates the draw under supervision, uses near-infrared light and Doppler ultrasound to locate a vein, and stops when its safety sensors detect a problem. Health systems considering deployment should translate the authorization conditions into staffing, cleaning, incident-response, training, and patient-selection procedures.
GenAI-enabled medical devices: discussion paper and October deadline
On August 18, the FDA issued a discussion paper on the regulation of generative-AI-enabled medical devices. The paper asks for input on risk assessment, premarket evaluation, postmarket monitoring, foundation models, and agentic AI systems. It outlines a possible two-axis risk framework and a premarket competency-assessment approach combining nonclinical benchmarking with clinical confirmation. 8
The affected groups include device manufacturers, clinicians, consumers, researchers, and other interested parties. Comments under docket FDA-2026-N-7874 are due October 19, 2026. Companies developing or using GenAI-enabled devices should assign owners for the questions on model risk, validation evidence, monitoring, foundation-model dependencies, and agentic behavior, then preserve the technical evidence behind any submission.
FTC
Doxo: $2.1 million bill-payment settlement
On August 17, the FTC announced that bill-payment firm Doxo would pay $2.1 million to settle allegations that it used misleading search ads to impersonate consumers' billers and charged consumers add-on fees. The FTC's case record identifies the matter as a new August 17 proceeding entry. 916
The current status is settlement, with the payment amount disclosed by the FTC. Doxo's next step is to carry out the settlement; bill-payment platforms and advertisers should review search-ad identity, landing-page ownership, fee disclosure, and consumer-routing controls against the allegations described by the agency.
Henkel/Liquid Nails: permanent injunction blocks $725 million acquisition
On August 17, the FTC said the U.S. District Court for the Southern District of New York granted a permanent injunction blocking Henkel's proposed $725 million acquisition of Liquid Nails from American Industrial Partners. The decision followed a seven-day trial. 10
The matter has moved from proposed transaction to final court injunction. The immediate next action is operational: the parties must treat the acquisition as blocked and reassess any integration, financing, disclosure, and strategic plans built around closing. The case also gives merger teams a completed court outcome to distinguish from a pending FTC complaint or administrative challenge.
Personalized pricing: policy process begins, deadline pending publication
On August 19, the FTC sought public comment on a proposed enforcement policy statement regarding personalized pricing under docket FTC-2026-1057. The release opens a formal policy-statement process for businesses that use customer or transaction data to set or vary prices. 11
The FTC states that comments are due 30 days after publication in the Federal Register. The exact Federal Register publication date and resulting deadline were not announced as of publication of this digest, so the date belongs in monitoring rather than the calendar table. Pricing, privacy, marketing, and consumer-protection teams should prepare an inventory of data inputs, segmentation logic, disclosures, testing records, and governance approvals so they can respond once the notice appears.
Manchester City Nissan: $4 million settlement over deceptive-fee allegations
On August 19, the FTC and Connecticut announced a $4 million settlement with Manchester City Nissan resolving allegations involving deceptive fees. 12
The matter is a settlement rather than a pending complaint. Dealers and other businesses that advertise prices should review how mandatory fees appear in initial offers, checkout flows, and consent records, while counsel should track the settlement's implementation terms in the agency and state records.
CareFirst/Amgen: FTC amicus brief on Enbrel patent rights
On August 21, the FTC filed an amicus brief in CareFirst of Maryland v. Amgen, alleging that Amgen acquired exclusive rights to patent applications shaped to cover Enbrel. The filing places the FTC's competition position before the court in litigation involving biologic-drug markets. 1317
The current status is an amicus filing; the FTC release states no monetary relief. The next action is to monitor the court's treatment of the brief and assess how the case may affect biologic competition, patent-licensing strategy, and future FTC scrutiny of rights obtained around follow-on products.
Action calendar
| Date | Matter | Action |
|---|---|---|
| October 19, 2026 | FDA docket FDA-2026-N-7874 | Submit comments on the discussion paper concerning GenAI-enabled medical devices. 8 |
| October 20, 2026 | SEC File No. S7-2026-27 | Submit comments on proposed Regulation Crypto Assets. 1 |
The FTC personalized-pricing deadline should be added after the Federal Register publishes the notice. The agency's announced rule is 30 days after publication, while the calendar-ready date remains pending.
Procedural status
The SEC items include one proposed rule, three filed complaints, and one subpoena-enforcement action. The complaints against Tricolor's former executives, Jesse R. Mitchell, and Gavin Wolfe and Jason Satsky seek court relief and remain pending. The 1859 Operating matter asks a court to compel investigative cooperation while the SEC continues fact-finding.
The FDA items include an accelerated approval with confirmatory trials ahead, a De Novo authorization with special controls, and a discussion paper with a fixed comment deadline. The FTC items include two settlements, a permanent court injunction, a proposed enforcement policy statement, and an amicus filing. Each category carries a different next step: comply with a settlement or injunction, prepare a comment, complete post-approval work, implement device controls, or monitor a pending court proceeding.
References
- 1Regulation Crypto Assets
federalregister.gov
- 2
- 3
- 4
- 5
- 6FDA approves Genglycos
fda.gov
- 7FDA authorizes Aletta
fda.gov
- 8
- 9FTC Doxo settlement
ftc.gov
- 10
- 11
- 12
- 13
- 14
- 15
- 16FTC Doxo case record
ftc.gov
- 17
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.